(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)-2-chloro-4-nitrobenzamide | 200729-53-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)-2-chloro-4-nitrobenzamide
• 英文别名: 1,2,3,4-tetrahydro-1-(2-chloro-4-nitrobenzoyl)-5H-l-benzazepine；(2-chloro-4-nitrophenyl)-(2,3,4,5-tetrahydro-1-benzazepin-1-yl)methanone
• CAS: 200729-53-9
• 化学式: C₁₇H₁₅ClN₂O₃
• 分子量: 330.771
• InChiKey: JNDYMCKBERDYHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)-2-chloro-4-nitrobenzamide 在 potassium carbonate 、 tin(ll) chloride 作用下， 以 N-甲基吡咯烷酮 、 乙醇 为溶剂， 反应 29.0h， 生成 (2-Chloro-4-diethylamino-phenyl)-(2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-methanone
  参考文献：
  名称：

  Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template

  摘要：

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.

  DOI：

  10.1021/jm000108p
• 作为产物：
  描述：

  2,3,4,5-四氢-1H-苯并[b]氮杂卓 、 2-氯-4-硝基苯甲酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以69%的产率得到(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)-2-chloro-4-nitrobenzamide
  参考文献：
  名称：

  Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template

  摘要：

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.

  DOI：

  10.1021/jm000108p

文献信息

• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05834461A1

  公开（公告）日：1998-11-10

  Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.

  本发明提供了一般式I的三环化合物：##STR1##，其在此定义下表现出V.sub.1和/或V.sub.2受体的拮抗活性，并在体内表现出利尿激素拮抗剂活性，以及使用这些化合物治疗由过多肾脏重吸收水分所特征的疾病的方法，以及制备这些化合物的方法。
• US5834461A
  申请人：——

  公开号：US5834461A

  公开（公告）日：1998-11-10
• Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine as a Template
  作者：Kazumi Kondo、Hidenori Ogawa、Tomoichi Shinohara、Muneaki Kurimura、Yoshihisa Tanada、Keizo Kan、Hiroshi Yamashita、Shigeki Nakamura、Takahiro Hirano、Yoshitaka Yamamura、Toyoki Mori、Michiaki Tominaga、Akiko Itai

  DOI：10.1021/jm000108p

  日期：2000.11.1

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.